Abstract
Inhalable lung surfactant-based carriers composed of synthetic phospholipids, dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol (DPPG), along with paclitaxel (PTX), were designed and optimized as respirable dry powders using organic solution co-spray-drying particle engineering design. These materials can be used to deliver and treat a wide variety of pulmonary diseases with this current work focusing on lung cancer. In particular, this is the first time dry powder lung surfactant-based particles have been developed and characterized for this purpose. Comprehensive physicochemical characterization was carried out to analyze the particle morphology, surface structure, solid-state transitions, amorphous character, residual water content, and phospholipid bilayer structure. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) spectroscopy. PTX loading was high, as quantified using UV-VIS spectroscopy, and sustained PTX release was measured over weeks. In vitro cellular characterization on lung cancer cells demonstrated the enhanced chemotherapeutic cytotoxic activity of paclitaxel from co-spray-dried DPPC/DPPG (co-SD DPPC/DPPG) lung surfactant-based carrier particles and the cytotoxicity of the particles via pulmonary cell viability analysis, fluorescent microscopy imaging, and transepithelial electrical resistance (TEER) testing at air-interface conditions. In vitro aerosol performance using a Next Generation Impactor™ (NGI™) showed measurable powder deposition on all stages of the NGI and was relatively high on the lower stages (nanometer aerodynamic size). Aerosol dispersion analysis of these high-performing DPIs showed mass median diameters (MMADs) that ranged from 1.9 to 2.3 μm with excellent aerosol dispersion performance as exemplified by high values of emitted dose, fine particle fractions, and respirable fractions.
[Figure not available: see fulltext.].
| Original language | English |
|---|---|
| Pages (from-to) | 1574-1587 |
| Number of pages | 14 |
| Journal | Ageing International |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 27 2014 |
Bibliographical note
Publisher Copyright:© 2014, American Association of Pharmaceutical Scientists.
Funding
The authors gratefully acknowledge financial support from the National Institutes of Health (NIH)-National Cancer Institute (NCI) Grant Number R25CA153954 and an NIH-NCI Cancer Nanotechnology Training Center (CNTC) Postdoctoral Traineeship awarded to SAM. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH. The authors thank Dr. Tonglei Li for XRPD and HSM access and Dr. J. Zach Hilt for ATR-FTIR access.
| Funders | Funder number |
|---|---|
| National Childhood Cancer Registry – National Cancer Institute | |
| National Institutes of Health (NIH) | |
| National Institutes of Health (NIH) | |
| National Childhood Cancer Registry – National Cancer Institute | R25CA153954 |
Keywords
- NBD-PC fluorescent microscopy imaging
- Next Generation Impactor (NGI)
- lung surfactant
- particle engineering design
- pulmonary cell lines
ASJC Scopus subject areas
- Health(social science)
